Agoracom: Small Cap Investment - Zenith Epigenetics

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

name Zenith Epigenetics
symbol NONE
exchange Private
financials View Filings
shares outstanding 134,990,827
industry Technology & Medical
transfer agent Computershare Trust Company of Canada
website http://www.zenithepigenet...

WebLink - Apr 12, 2021 11:13AM
AACR 2021 Poster: COMBINATION OF ZEN-3694 WITH TALAZOPARIB IS A NOVEL THERAPEUTIC APPROACH IN ER POSITIVE BREAST CANCER RESISTANT TO CDK4/6 INHIBITORS, INDEPENDENT OF BRCA STATUS
Press Release - Mar 15, 2021 01:16PM
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
WebLink - Feb 08, 2021 12:47PM
Zenith Epigenetics AGM Corporate Update 12/22/2020
WebLink - Jan 06, 2021 10:51AM
AGM 12/22/2020 transcript c/o imtesty
Press Release - Dec 23, 2020 04:29PM
Zenith Announces Voting Results from the 2020 Annual and Special Meeting of Shareholders

Re: Exempt Dist.

narmac

Apr 16, 2021 05:41PM

Apr 15, 2021 06:32AM

Apr 15, 2021 12:19AM

fuzzyjr

Apr 13, 2021 01:37PM

Apr 13, 2021 09:31AM

Dec 30, 2020 11:52PM

Dec 30, 2020 06:16PM

Dec 31, 2020 08:38AM

Toinv

Dec 29, 2020 01:07PM